Advertisement

Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors

  • Stina Wickström
  • Tanja LövgrenEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1913)

Abstract

Autologous, in vitro-expanded tumor-infiltrating lymphocytes (TIL) have been successfully used for treatment of melanoma patients. Expansion of TIL from tumors is usually performed in two steps. The details of the procedure differ between different laboratories, but the general concept remains the same. In the first step, small fragments of a tumor are placed in culture medium containing one or more T cell stimulating growth factors. Here the most common protocol using interleukin (IL)-2 is described. The length of the first step is flexible to allow generation of enough cell to start the second step of the procedure. The second step is a so-called rapid expansion protocol (REP) where harvested TIL from the first step are induced to massive proliferation via triggering of their T cell receptor (TCR) complex in presence of an excess of feeder cells and, again, T cell stimulating growth factors. This second expansion step is usually around 2 weeks in length. Here will be described a REP that uses soluble anti-CD3 antibodies for TCR triggering, irradiated peripheral blood mononuclear cells (PBMC) as feeder cells, and IL-2 as the T cell growth factor. Furthermore, the described protocol utilizes gas-permeable cell culture flasks that yield large number of cells similar to conventional bioreactors but using standard laboratory equipment.

Key words

Immunotherapy T cells Tumor-infiltrating lymphocytes In vitro expansion Adoptive cell transfer Interleukine-2 Anti-CD3 Feeder cells Gas-permeable cell culture flasks 

References

  1. 1.
    Rosenberg SA, Packard BS, Aebersold PM et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676–1680.  https://doi.org/10.1056/NEJM198812223192527CrossRefPubMedGoogle Scholar
  2. 2.
    Rosenberg SA, Yannelli JR, Yang JC et al (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86(15):1159–1166CrossRefGoogle Scholar
  3. 3.
    Besser MJ, Shapira-Frommer R, Schachter J (2015) Tumor-infiltrating lymphocytes: clinical experience. Cancer J 21(6):465–469.  https://doi.org/10.1097/PPO.0000000000000154CrossRefPubMedGoogle Scholar
  4. 4.
    Besser MJ, Shapira-Frommer R, Treves AJ et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16(9):2646–2655.  https://doi.org/10.1158/1078-0432.CCR-10-0041CrossRefPubMedGoogle Scholar
  5. 5.
    Ellebaek E, Iversen TZ, Junker N et al (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169.  https://doi.org/10.1186/1479-5876-10-169CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257(1):56–71.  https://doi.org/10.1111/imr.12132CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pilon-Thomas S, Kuhn L, Ellwanger S et al (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35(8):615–620.  https://doi.org/10.1097/CJI.0b013e31826e8f5fCrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Poschke I, Lövgren T, Adamson L et al (2014) A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 63(10):1061–1071.  https://doi.org/10.1007/s00262-014-1575-2CrossRefGoogle Scholar
  9. 9.
    Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770.  https://doi.org/10.1158/1078-0432.CCR-12-1177CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bajgain P, Mucharla R, Wilson J et al (2014) Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev 1:14015.  https://doi.org/10.1038/mtm.2014.15CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Forget MA, Haymaker C, Dennison JB et al (2016) The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology 5(2):e1057386.  https://doi.org/10.1080/2162402X.2015.1057386CrossRefPubMedGoogle Scholar
  12. 12.
    Forget MA, Malu S, Liu H et al (2014) Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 37(9):448–460.  https://doi.org/10.1097/CJI.0000000000000056CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jin J, Sabatino M, Somerville R et al (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35(3):283–292.  https://doi.org/10.1097/CJI.0b013e31824e801fCrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Alvarez-Fernandez C, Escriba-Garcia L, Vidal S et al (2016) A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J Transl Med 14(1):214.  https://doi.org/10.1186/s12967-016-0973-yCrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cieri N, Camisa B, Cocchiarella F et al (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4):573–584.  https://doi.org/10.1182/blood-2012-05-431718CrossRefPubMedGoogle Scholar
  16. 16.
    Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101(7):1969–1974.  https://doi.org/10.1073/pnas.0307298101CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li Y, Bleakley M, Yee C (2005) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175(4):2261–2269CrossRefGoogle Scholar
  18. 18.
    Redeker A, Arens R (2016) Improving adoptive T Cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination. Front Immunol 7:345.  https://doi.org/10.3389/fimmu.2016.00345CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chacon JA, Pilon-Thomas S, Sarnaik AA et al (2013) Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2(9):e25581.  https://doi.org/10.4161/onci.25581CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chacon JA, Wu RC, Sukhumalchandra P et al (2013) Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8(4):e60031.  https://doi.org/10.1371/journal.pone.0060031CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Donia M, Larsen SM, Met O et al (2014) Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy 16(8):1117–1120.  https://doi.org/10.1016/j.jcyt.2014.02.004CrossRefPubMedGoogle Scholar
  22. 22.
    Klapper JA, Thomasian AA, Smith DM et al (2009) Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345(1-2):90–99.  https://doi.org/10.1016/j.jim.2009.04.009CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Oncology-PathologyKarolinska InstitutetStockholmSweden
  2. 2.Department of Immunology, Genetics and PathologyUppsala UniversityUppsalaSweden

Personalised recommendations